News & Events



Rehovot, Israel Sept 20, 2021

Based of the satisfactory safety data of VIDAC VDA 1102 on selected patients, Vidac Pharma received authorization to widen the scope of the trial to CTCL whole spectrum of conditions.

“We are very satisfied with the results of the first step which on top of the safety results granted to our trial a dose ranging proto...




Rehovot, Israel Sept 13, 2021

Vidac Pharma Ltd. announces that it was granted a USA Patent for a new chemical family of compounds targeting the HK2-VDAC system developed by the company. The new compounds are hydrophilic and were developed to fit systemic use such as IV, IM and/or Per-Os use. “This is opening the way to explore possible treatment o...




NESS-ZIONA, Israel, April 19, 2021 /PRNewswire/ -- Vidac Pharma LTD (Vidac) a clinical-stage Israel biopharmaceutical company, announced today that it has signed an agreement with GEM Global Yield LLC SCS ("GEM") a Luxemburg-based private alternative investment group for a EUR 20 million capital commitment.

Under the agreement, GEM commits to prov...




Jerusalem, Israel, February 09 2021 – Vidac Pharma Ltd announces inclusion of the first Patient in a Placebo controlled Phase II study in early forms of Cutaneous T-Cell Lymphoma treated with its first in class drug VDA 1102 . VDA 1102 disrupt the binding of the glycolytic enzyme HK2 over expressed in Cancer Cells from the VDAC channel. This causes...




Jerusalem, Israel, December 16 2018 – Vidac Pharma, a clinical stage oncology and dermatology focused pharmaceutical company, announce the publication of its latest article in the prestigious Journal of Investigative Dermatology (2018, vol 138:2635-2643), discussing the discovery of Vidac’s anti-cancer drug VDA-1102 and its pre-clinical characteriz...




Jerusalem, Israel, November 4, 2018 – Vidac Pharma, a clinical stage oncology-focused immune-metabolism company, today announced that it will present a poster at the Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting in Washington, DC. The poster entitled “Modulating Hexokinase 2 (HK2) as a Novel Approach for Simultaneous Targeting of t...




Jerusalem, Israel, July 10 2018 – Vidac Pharma, a clinical stage oncology and dermatology focused pharmaceutical company, today announced initiation of a Phase 2b clinical trial of VDA-1102 ointment to treat subjects with actinic keratosis (AK), an early stage of cutaneous squamous cell carcinoma (cSCC), which is a common form of non-melanoma skin...




Jerusalem, Israel, June 20, 2018 – Vidac Pharma, a clinical stage oncology-focused immune-metabolism company, today announced that it will present a poster entitled “Modulating Hexokinase 2 (HK2) as a Novel Approach to Target Metabolic Immuno-Oncology” at the 25th Biennial Congress of the European Association for Cancer Research (EACR25) in Amsterd...




Jerusalem, Israel, April 4, 2018 – Vidac Pharma, a clinical stage oncology and dermatology-focused biopharmaceutical company, today announced that it will present an immono-metabolism poster at the AACR Annual Meeting 2018 in Chicago, Illinois. The poster entitled: "A Bi-functional Mechanism of Action: Activating the NLRP3 Inflammasome in Macrophag...




Jerusalem, Israel, December 12, 2016 – Vidac Pharma, a clinical-stage oncology-focused pharmaceutical company, today announced that the ongoing Phase 2 study with VDA-1102 ointment, a potent selective VDAC/HK2 modulator, in actinic keratosis (AK) met a pre-determined interim analysis criterion. The drug candidate is being developed by Vidac as a fi...




Jerusalem, Israel, July 29, 2016 – Vidac Pharma, a clinical stage oncology focused pharmaceutical company, today announced that the Company has initiated a Phase 2 trial with VDA-1102 ointment, a potent selective VDAC/HK2 modulator, to treat subjects with actinic keratosis (AK), an early form of cutaneous squamous cell carcinoma (cSCC). The drug...




Vidac Pharma reports positive results from Phase 2A Proof-of-concept trial of VDA-1102 OINTMENT in Actinic Keratosis

  • Establishes that VDA-1102 ointment is well-tolerated, non-irritating and safe
  • Demonstrates reduction of number of actinic keratosis lesions in treatment field

Jerusalem, Israel, October 12, 2017 – Vidac Pharma, a clinical-...




Jerusalem, Israel, December 6, 2017 – Vidac Pharma, a clinical stage oncology and dermatology-focused biopharmaceutical company, today announced that it will participate as Company Spotlight presenter at the 4th Annual Dermatology Innovation Forum. The company presentation will be on Thursday, February 15, 2018 at 2:40 pm PT at the Manchester Grand...




Jerusalem, Israel, January 23, 2018 – Vidac Pharma, a clinical-stage oncology and dermatology-focused biopharmaceutical company, today announced that Oren M. Becker, PhD, President and Chief Executive Officer, will present at the 2018 BIO CEO & Investor Conference on Monday, February 12, 2018 at 3:00 pm EST at the Marriott Marquis in New York City...




Jerusalem, Israel, June 30, 2016 – Vidac Pharma, a clinical stage oncology focused pharmaceutical company, today announced that the Company has completed a Phase 1a trial of VDA-1102 ointment, a topical ointment formulation of VDA-1102, a potent selective VDAC/HK2 modulator, for the treatment of actinic keratosis (AK) and other hyperproliferative d...




Jerusalem, Israel, January 1, 2017 – Vidac Pharma, a clinical-stage oncology-focused pharmaceutical company, today announced the appointment of Dr. Chaim Brickman as the company's Chief Medical Officer, and the appointment of Dr. Vered Behar as the company's Chief Science Officer. Dr. Brickman was formerly Vidac's Vice President of Medical Affairs...




Jerusalem, Israel, June 29, 2016 – Vidac Pharma, a privately-held clinical stage pharmaceutical company developing novel small molecule therapeutics for the treatment of cancer and oncodermatology disease, announced today that it has closed a $9 million a Series A financing round. The financing was led by a new investor, Israel Biotech Fund. Existi...




Jerusalem, Israel, December 30, 2015 – Vidac Pharma, a drug discovery and development company, today announced the filing of an Investigational New Drug (IND) application with the U.S. FDA for VDA-1102 topical skin ointment, its highly selective, proprietary VDAC/HK2 modulator for the treatment of actinic keratosis (AK), an early form of cutaneous...




Jerusalem, Israel, November 15, 2014 – Vidac Pharma, a drug discovery and development company, today announced the appointment of Chaim M. Brickman, M.D. as its vice president of clinical affairs. Chaim will oversee all clinical development activities for the company, as Vidac rapidly advances its product candidates in human clinical trials for a r...




Ness Ziona, Israel, August 19, 2014 – Vidac Pharma, a drug discovery and development company, today announced the appointment of Dr. Paul Salama as its vice president of chemistry, manufacturing, and control (CMC). Dr. Salama brings to Vidac more than 20 years of experience in medicinal chemistry, formulation, GMP process chemistry and manufacturin...




Jerusalem, Israel, February 25, 2016 – Vidac Pharma, a clinical stage drug development company, today announced the initiation of Phase I first-in-human studies with VDA-1102 ointment, its highly selective, proprietary VDAC/HK2 modulator for the treatment of actinic keratosis (AK), an early form of cutaneous squamous cell carcinoma (cSCC).

As a se...